HMGB1 increases RAGE expression in vascular smooth muscle cells via ERK and p-38 MAPK-dependent pathways
The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given t...
Saved in:
Published in | The Korean journal of physiology & pharmacology Vol. 26; no. 5; pp. 389 - 396 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
The Korean Physiological Society and The Korean Society of Pharmacology
01.09.2022
대한약리학회 |
Subjects | |
Online Access | Get full text |
ISSN | 1226-4512 2093-3827 |
DOI | 10.4196/kjpp.2022.26.5.389 |
Cover
Abstract | The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures. |
---|---|
AbstractList | The increased expression of receptors for advanced glycation endproduct (RAGE) is known as a key player in the progression of vascular remodeling.
However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)- induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPKRAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures. KCI Citation Count: 0 The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures.The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures. The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However, the precise signal pathways regulating RAGE expression in vascular smooth muscle cells (VSMCs) in the injured vasculatures are unclear. Given the importance of mitogen-activated protein kinase (MAPK) signaling in cell proliferation, we investigated the importance of MAPK signaling in high-mobility group box 1 (HMGB1)-induced RAGE expression in VSMCs. In HMGB1 (100 ng/ml)-stimulated human VSMCs, the expression of RAGE mRNA and protein was increased in association with an increase in AGE-induced VSMC proliferation. The HMGB1-induced RAGE expression was attenuated in cells pretreated with inhibitors for ERK (PD98059, 10 μM) and p38 MAPK (SB203580, 10 μM) as well as in cells deficient in ERK and p38 MAPK using siRNAs, but not in cells deficient of JNK signaling. In cells stimulated with HMGB1, the phosphorylation of ERK, JNK, and p38 MAPK was increased. This increase in ERK and p38 MAPK phosphorylation was inhibited by p38 MAPK and ERK inhibitors, respectively, but not by JNK inhibitor. Moreover, AGE-induced VSMC proliferation in HMGB1-stimulated cells was attenuated in cells treated with ERK and p38 MAPK inhibitors. Taken together, our results indicate that ERK and p38 MAPK signaling are involved in RAGE expression in HMGB1-stimulated VSMCs. Thus, the ERK/p38 MAPK-RAGE signaling axis in VSMCs was suggested as a potential therapeutic target for vascular remodeling in the injured vasculatures. |
Author | Jeon, Eun Yeong Kim, Ji Won Jang, Eun Jeong Baek, Seung Eun Kim, Ju Yeon Kim, Heejeong Kim, Chi Dae |
AuthorAffiliation | 1 Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea 3 Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Korea 2 Department of Laboratory Medicine, Pusan National University Hospital, Busan 49241, Korea |
AuthorAffiliation_xml | – name: 3 Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Korea – name: 1 Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea – name: 2 Department of Laboratory Medicine, Pusan National University Hospital, Busan 49241, Korea |
Author_xml | – sequence: 1 givenname: Eun Jeong surname: Jang fullname: Jang, Eun Jeong organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea – sequence: 2 givenname: Heejeong surname: Kim fullname: Kim, Heejeong organization: Department of Laboratory Medicine, Pusan National University Hospital, Busan 49241, Korea – sequence: 3 givenname: Seung Eun surname: Baek fullname: Baek, Seung Eun organization: Department of Anatomy, School of Medicine, Pusan National University, Yangsan 50612, Korea – sequence: 4 givenname: Eun Yeong surname: Jeon fullname: Jeon, Eun Yeong organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea – sequence: 5 givenname: Ji Won surname: Kim fullname: Kim, Ji Won organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea – sequence: 6 givenname: Ju Yeon surname: Kim fullname: Kim, Ju Yeon organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea – sequence: 7 givenname: Chi Dae surname: Kim fullname: Kim, Chi Dae organization: Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Korea |
BackLink | https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002873479$$DAccess content in National Research Foundation of Korea (NRF) |
BookMark | eNp9UctO3DAUtRAVTCk_wMrLqlKCH4ljbypN0XRAgFqNYG15nJuOO4mT2slQ_r4eBhbtoqu7OI97dM57dOx7DwhdUJIXVInL7c9hyBlhLGciL3Mu1RGaMaJ4xiWrjtGMMiayoqTsFJ3H6NaEyJKUkqgTdMoF4ariaoY21_fLLxQ7bwOYCBGv5ssFht9DgCTqfULwzkQ7tSbg2PX9uMHdFG0L2ELbRrxzBi9Wt9j4Gg_pN76ff7_NahjA1-BHPJhx82Se4wf0rjFthPPXe4Yevy4erq6zu2_Lm6v5XWYLWoyZIaypioZxZSoBDVGVKhtOFOVUWisJCFNzCoRJUYt1YYWA2jAlJBcFUGj4Gfp08PWh0VvrdG_cy_3R623Q89XDjaaEpL4KmcifD-RhWndQ2xQ4mFYPwXUmPL9I_0a82ySjnVYFr7ioksHHV4PQ_5ogjrpzcV-M8dBPUbOKSCaopCpR5YFqQx9jgEZbN5oxdZycXZtC6f2wej-s3g-rmdClTkGTlP0jfUv4H9Efp7aneg |
CitedBy_id | crossref_primary_10_4196_kjpp_2024_28_5_449 crossref_primary_10_4196_kjpp_2024_28_6_503 crossref_primary_10_1007_s11010_024_05132_8 crossref_primary_10_3390_nu14194047 crossref_primary_10_58502_DTT_24_0009 crossref_primary_10_1093_cvr_cvad189 crossref_primary_10_4196_kjpp_24_220 crossref_primary_10_2147_DMSO_S496360 |
Cites_doi | 10.1161/01.CIR.103.24.2980 10.1038/382685a0 10.1002/jcb.25682 10.4103/2319-4170.117622 10.1189/jlb.0908548 10.1182/blood.V87.6.2095.bloodjournal8762095 10.1038/emm.2006.62 10.1038/onc.2012.631 10.1016/j.cardiores.2005.05.004 10.14670/HH-29.235 10.1016/j.bbamcr.2008.11.016 10.1016/j.vph.2019.04.001 10.1016/j.cardiores.2005.08.002 10.1007/s11010-015-2396-0 10.1161/01.ATV.0000145573.36113.8a 10.1371/journal.pone.0128881 10.1016/S1043-2760(00)00311-8 10.1096/fj.06-5867fje 10.1111/ajt.12781 10.1016/j.intimp.2005.05.003 10.1155/2015/354517 10.1007/s00125-009-1458-9 10.1161/ATVBAHA.107.159327 10.1146/annurev-immunol-030409-101323 10.1172/JCI200114002 10.1080/15384101.2015.1100771 10.1161/01.ATV.0000131783.74034.97 |
ContentType | Journal Article |
Copyright | Copyright © Korean J Physiol Pharmacol 2022 |
Copyright_xml | – notice: Copyright © Korean J Physiol Pharmacol 2022 |
DBID | AAYXX CITATION 7X8 5PM ACYCR |
DOI | 10.4196/kjpp.2022.26.5.389 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Korean Citation Index |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 2093-3827 |
EndPage | 396 |
ExternalDocumentID | oai_kci_go_kr_ARTI_10038948 PMC9437367 10_4196_kjpp_2022_26_5_389 |
GroupedDBID | --- 5-W 5GY 8JR 8XY 9ZL AAYXX ABDBF ACUHS ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK E3Z EBD EF. ESX F5P GX1 HYE MK0 OK1 P2P P5Y P6G RPM TR2 TUS 7X8 5PM .UV 53G ABPTK ACYCR KVFHK |
ID | FETCH-LOGICAL-c414t-a02f74f239a76ef09795f3091318cc80e6ad31e0286d6b4c66eda2968364e1ef3 |
ISSN | 1226-4512 |
IngestDate | Tue Nov 21 21:39:56 EST 2023 Thu Aug 21 18:11:09 EDT 2025 Fri Jul 11 08:15:07 EDT 2025 Tue Jul 01 02:33:17 EDT 2025 Thu Apr 24 23:02:26 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 5 |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c414t-a02f74f239a76ef09795f3091318cc80e6ad31e0286d6b4c66eda2968364e1ef3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Author contributions: E.J.J. and C.D.K. designed the study. S.E.B., E.Y.J., J.W.K., and J.Y.K. performed the experiments. H.K. and C.D.K. wrote the manuscript. These authors contributed equally to this work. |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC9437367 |
PMID | 36039739 |
PQID | 2708261819 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_10038948 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9437367 proquest_miscellaneous_2708261819 crossref_citationtrail_10_4196_kjpp_2022_26_5_389 crossref_primary_10_4196_kjpp_2022_26_5_389 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2022-09-01 20220901 2022-09 |
PublicationDateYYYYMMDD | 2022-09-01 |
PublicationDate_xml | – month: 09 year: 2022 text: 2022-09-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | The Korean journal of physiology & pharmacology |
PublicationYear | 2022 |
Publisher | The Korean Physiological Society and The Korean Society of Pharmacology 대한약리학회 |
Publisher_xml | – name: The Korean Physiological Society and The Korean Society of Pharmacology – name: 대한약리학회 |
References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref27 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref25 doi: 10.1161/01.CIR.103.24.2980 – ident: ref12 doi: 10.1038/382685a0 – ident: ref6 doi: 10.1002/jcb.25682 – ident: ref1 doi: 10.4103/2319-4170.117622 – ident: ref2 doi: 10.1189/jlb.0908548 – ident: ref17 doi: 10.1182/blood.V87.6.2095.bloodjournal8762095 – ident: ref26 doi: 10.1038/emm.2006.62 – ident: ref8 doi: 10.1038/onc.2012.631 – ident: ref18 doi: 10.1016/j.cardiores.2005.05.004 – ident: ref24 doi: 10.14670/HH-29.235 – ident: ref11 doi: 10.1016/j.bbamcr.2008.11.016 – ident: ref10 doi: 10.1016/j.vph.2019.04.001 – ident: ref14 doi: 10.1016/j.cardiores.2005.08.002 – ident: ref27 doi: 10.1007/s11010-015-2396-0 – ident: ref3 doi: 10.1161/01.ATV.0000145573.36113.8a – ident: ref21 doi: 10.1371/journal.pone.0128881 – ident: ref22 doi: 10.1016/S1043-2760(00)00311-8 – ident: ref7 doi: 10.1096/fj.06-5867fje – ident: ref5 doi: 10.1111/ajt.12781 – ident: ref15 doi: 10.1016/j.intimp.2005.05.003 – ident: ref19 doi: 10.1155/2015/354517 – ident: ref13 doi: 10.1007/s00125-009-1458-9 – ident: ref16 doi: 10.1161/ATVBAHA.107.159327 – ident: ref9 doi: 10.1146/annurev-immunol-030409-101323 – ident: ref23 doi: 10.1172/JCI200114002 – ident: ref4 doi: 10.1080/15384101.2015.1100771 – ident: ref20 doi: 10.1161/01.ATV.0000131783.74034.97 |
SSID | ssib008505809 ssj0064464 |
Score | 2.2916236 |
Snippet | The increased expression of receptors for advanced glycation end-product (RAGE) is known as a key player in the progression of vascular remodeling. However,... The increased expression of receptors for advanced glycation endproduct (RAGE) is known as a key player in the progression of vascular remodeling. However, the... |
SourceID | nrf pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
StartPage | 389 |
SubjectTerms | Original 약리학 |
Title | HMGB1 increases RAGE expression in vascular smooth muscle cells via ERK and p-38 MAPK-dependent pathways |
URI | https://www.proquest.com/docview/2708261819 https://pubmed.ncbi.nlm.nih.gov/PMC9437367 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002873479 |
Volume | 26 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | The Korean Journal of Physiology & Pharmacology, 2022, 26(5), , pp.389-396 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLW2ISFeEDAQ4yYjCC9RSmI7jv2YXthgGpqmTdpblKTOVsbSqmmB8ev5bCdpM6Zp8BJZsWO7OSfJsfv5GKH3nLOsUPAgZSEJPUZV6IGqJl6e-TKP8kD4Qq93PvjK907Yl9PwdGPz_lrU0nKR9fLfN64r-R9U4RzgqlfJ_gOybaVwAtKALxwBYTjeCeO9g91-4E5KrfwqVblH-u8h9auObTUxjG2kaXU5BVDcy2UFlbh6vr5yf0xSd3S0b80CPCrcg_hw32v2xV1o09Xzn-lVta5gNa_2p_NmAr8Ws2aCxNo5aS7NVobY7ZS9Mxo4cuTEoUkMdYgFJGLfsdtf2iKx05cmZ6iLxIMbivSdvu_0A50jTPGmuvWG4BrBOg1J4dhdW5o5DhgeN0FclpW6ajFoWg8daVqHRH-os2Ju-mOzpEnEUH7trQ4a02NhHa-tzDniSwo31hoT1G9vanczqoUAtVvtXv_GMHhnATEuvs203SkhPcJ7Ya-9dN3Q-9qHtmPpfZFPkrNpcjFPYODyWVtHQxVMbKJ7JIpMwMHu6erNK0CoGqM1qzFAxBpjtPaH2eVgumsf_-5YR3JtlvOiM5rqxgKviavjR-hhPSrCsaX4Y7ShyidoOy7TxfTyCn_Ahy29ttG5YT1uWY816_GK9ZCDG9Zjy3psWY8N6zGwHgPrMbAea9bjLutxw_qn6OTT6Hiw59X7hXg5C9jCS31SRKwgVKYRV4UvIxkWVBvfBiLPha94OqaBAkXNxzxjOedqnBLJBeVMBaqgz9BWOS3Vc4QJHQvBhQp4RBnPmYBhCwlzPxCcqkwWOyhobmmS12b6ek-X7wBkomFINAyJhiEhPAkTgGEHue01M2slc2vpd4CUocktdNlBbxskE_gu6NuYlmq6rBISgbjnoN-hpqgDcdu4rrebU07OjcO81IZnPHpxpz68RA9Wz-wrtLWYL9VrUOqL7I0h8R9UG9F0 |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HMGB1+increases+RAGE+expression+in+vascular+smooth+muscle+cells+via+ERK+and+p-38+MAPK-dependent+pathways&rft.jtitle=The+Korean+journal+of+physiology+%26+pharmacology&rft.au=%EC%9E%A5%EC%9D%80%EC%A0%95&rft.au=%EA%B9%80%ED%9D%AC%EC%A0%95&rft.au=%EB%B0%B1%EC%8A%B9%EC%9D%80&rft.au=%EC%A0%84%EC%9D%80%EC%98%81&rft.date=2022-09-01&rft.pub=%EB%8C%80%ED%95%9C%EC%95%BD%EB%A6%AC%ED%95%99%ED%9A%8C&rft.issn=1226-4512&rft.eissn=2093-3827&rft.spage=389&rft.epage=396&rft_id=info:doi/10.4196%2Fkjpp.2022.26.5.389&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_10038948 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1226-4512&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1226-4512&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1226-4512&client=summon |